I am excited to announce CLSDF has added another 100 subscribers; the blog is now north of 500, passing the 400 mark only 3 months ago in March. My infinite appreciation to all of you for subscribing, your feedback (both positive and negative) is treasured and motivating. If you find CLSDF to be of continuing [...]

• 415http://clsdf.com/2008/06/clsdf-subscriber-growth-update-2/CLSDF%3A+Subscriber+Growth+Update2008-06-12+14%3A36%3A00admin

Ceragenix Pharmaceuticals (OTCBB: CGXP) announced positive results from its investigator-blinded pilot study comparing the safety and efficacy of EpiCeram® Skin Barrier Emulsion to that of Elidel® cream from Novartis (NYSE: NVS), a standard non-steroidal therapy in the treatment of mild-to-moderate pediatric atopic dermatitis (AD). Both EpiCeram® and Elidel® cream produced significant improvement in patients’ conditions [...]

• 414http://clsdf.com/2008/06/ceragenix-pilot-study-results-for-epiceram%c2%ae/Ceragenix+Pilot+Study+Results+for+EpiCeram%C2%AE2008-06-12+14%3A32%3A00admin